How long will chronic myeloid leukemia patients treated with imatinib mesylate live?

被引：19
作者：
Hasford, J
Pfirrmann, M
Hochhaus, A
机构：
[1] Univ Munich, Dept Med Informat Biometry & Epidemiol, IBE, Leukemia & Lymphoma Biostat Grp, D-81377 Munich, Germany
[2] Heidelberg Univ, Fak Klin Med Mannheim, Med Klin 3, D-6800 Mannheim, Germany
来源：
LEUKEMIA | 2005年 / 19卷 / 04期
关键词：
D O I：
10.1038/sj.leu.2403686
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：497 / 499
页数：3
相关论文
共 10 条
[1]   Treatment options for chronic myelold leukemia: imatinib versus interferon versus allogeneic transplant [J].
Angstreich, GR ;
Smith, BD ;
Jones, RJ .
CURRENT OPINION IN ONCOLOGY, 2004, 16 (02) :95-99
[2]   Chronic myeloid leukemia and interferon-α:: a study of complete cytogenetic responders [J].
Bonifazi, F ;
de Vivo, A ;
Rosti, G ;
Guilhot, F ;
Guilhot, J ;
Trabacchi, E ;
Hehlmann, R ;
Hochhaus, A ;
Shepherd, PCA ;
Steegmann, JL ;
Kluin-Nelemans, HC ;
Thaler, J ;
Simonsson, B ;
Louwagie, A ;
Reiffers, J ;
Mahon, FX ;
Montefusco, E ;
Alimena, G ;
Hasford, J ;
Richards, S ;
Saglio, G ;
Testoni, N ;
Martinelli, G ;
Tura, S ;
Baccarani, M .
BLOOD, 2001, 98 (10) :3074-3081
[3]   A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa [J].
Hasford, J ;
Pfirrmann, M ;
Hehlmann, R ;
Allan, NC ;
Baccarani, M ;
Kluin-Nelemans, JC ;
Alimena, G ;
Steegmann, JL ;
Ansari, H .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (11) :850-858
[4]   Imatinib therapy in chronic myelogenous leukemia:: strategies to avoid and overcome resistance [J].
Hochhaus, A ;
La Rosée, P .
LEUKEMIA, 2004, 18 (08) :1321-1331
[5]   Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [J].
Hughes, TP ;
Kaeda, J ;
Branford, S ;
Rudzki, Z ;
Hochhaus, A ;
Hensley, ML ;
Gathmann, I ;
Bolton, AE ;
van Hoomissen, IC ;
Goldman, JM ;
Radich, JP ;
Taylor, K ;
Durrant, S ;
Schwarer, A ;
Joske, D ;
Seymour, J ;
Grigg, A ;
Ma, D ;
Arthur, C ;
Bradstock, K ;
Joshua, D ;
Lechner, K ;
Verhoef, G ;
Louwagie, A ;
Martiat, P ;
Straetmans, N ;
Bosly, A ;
Shepherd, J ;
Shustik, C ;
Lipton, J ;
Kovacs, DM ;
Turner, AR ;
Nielsen, JL ;
Birgens, H ;
Bjerrum, OW ;
Guilhot, F ;
Reiffers, J ;
Rousselot, P ;
Facon, T ;
Harousseau, JL ;
Tulliez, M ;
Guerci, A ;
Blaise, D ;
Maloisel, F ;
Michallet, M ;
Fischer, T ;
Hossfeld, D ;
Mertelsmann, R ;
Andreesen, R ;
Nerl, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1423-1432
[6]   PROLONGED SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA AFTER CYTOGENETIC RESPONSE TO INTERFERON-ALPHA THERAPY [J].
KANTARJIAN, HM ;
SMITH, TL ;
OBRIEN, S ;
BERAN, M ;
PIERCE, S ;
TALPAZ, M ;
ROBERTSON, L ;
KOLLER, C ;
ESTEY, E ;
KEATING, MJ .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (04) :254-261
[7]   Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α [J].
Kantarjian, HM ;
Cortes, JE ;
O'Brien, S ;
Luthra, R ;
Giles, F ;
Verstovsek, S ;
Facerl, S ;
Thomas, D ;
Garcia-Manero, G ;
Rios, MB ;
Shan, J ;
Jones, D ;
Talpaz, M .
BLOOD, 2004, 104 (07) :1979-1988
[8]   Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C [J].
Müller, MC ;
Gattermann, N ;
Lahaye, T ;
Deininger, MWN ;
Berndt, A ;
Fruehauf, S ;
Neubauer, A ;
Fischer, T ;
Hossfeld, DK ;
Schneller, F ;
Krause, SW ;
Nerl, C ;
Sayer, HG ;
Ottmann, OG ;
Waller, C ;
Aulitzky, W ;
le Coutre, P ;
Freund, M ;
Merx, K ;
Paschka, P ;
König, H ;
Kreil, S ;
Berger, U ;
Gschaidmeier, H ;
Hehlmann, R ;
Hochhaus, A .
LEUKEMIA, 2003, 17 (12) :2392-2400
[9]   Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].
O'Brien, SG ;
Guilhot, F ;
Larson, RA ;
Gathmann, I ;
Baccarani, M ;
Cervantes, F ;
Cornelissen, JJ ;
Fischer, T ;
Hochhaus, A ;
Hughes, T ;
Lechner, K ;
Nielsen, JL ;
Rousselot, P ;
Reiffers, J ;
Saglio, G ;
Shepherd, J ;
Simonsson, B ;
Gratwohl, A ;
Goldman, JM ;
Kantarjian, H ;
Taylor, K ;
Verhoef, G ;
Bolton, AE ;
Capdeville, R ;
Druker, BJ ;
Durrant, S ;
Schwarer, A ;
Joske, D ;
Seymour, J ;
Grigg, A ;
Ma, D ;
Arthur, C ;
Bradstock, K ;
Joshua, D ;
Louwagie, A ;
Martiat, P ;
Straetmans, N ;
Bosly, A ;
Shustik, C ;
Lipton, J ;
Forrest, D ;
Walker, I ;
Roy, DC ;
Rubinger, M ;
Bence-Bruckler, I ;
Kovacs, M ;
Turner, AR ;
Birgens, H ;
Bjerrum, O ;
Facon, T .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) :994-1004
[10]   Optimizing treatment of chronic myeloid leukemia: A rational approach [J].
Stone, RM .
ONCOLOGIST, 2004, 9 (03) :259-270
1